Phase I study of combination treatment with PTK 787/ZK 222584 (PTK/ZK) and cetuximab for patients with advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and toxicity analysis

被引：0
|
作者：
Langenberg, M. H. [1 ,2 ,3 ]
Witteveen, P. O. [1 ,2 ,3 ]
Lankheet, N. [1 ,2 ,3 ]
Roodhart, J. M. [1 ,2 ,3 ]
Rosing, H. [1 ,2 ,3 ]
Beijnen, J. H. [1 ,2 ,3 ]
Voest, E. E. [1 ,2 ,3 ]
机构：
[1] Univ Med Ctr Utrecht, Utrecht, Netherlands
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Slotervaart Hosp, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2575
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis
    Langenberg, Marlies H. G.
    Witteveen, Petronella O.
    Lankheet, Nienke A. G.
    Roodhart, Jeanine M. L.
    Rosing, Hilde
    van den Heuvel, Ingeborg J. G. M.
    Beijnen, Jos H.
    Voest, Emile E.
    NEOPLASIA, 2010, 12 (02): : 206 - 213
  • [2] Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer
    Thomas, AL
    Morgan, B
    Horsfield, MA
    Higginson, A
    Kay, A
    Lee, L
    Masson, E
    Puccio-Pick, M
    Laurent, D
    Steward, WP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4162 - 4171
  • [3] A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors
    Sharma, Sunil
    Freeman, Burgess
    Turner, Jeanette
    Symanowski, James
    Manno, Phillip
    Berg, William
    Vogelzang, Nicholas
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (01) : 63 - 65
  • [4] A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors
    Sunil Sharma
    Burgess Freeman
    Jeanette Turner
    James Symanowski
    Phillip Manno
    William Berg
    Nicholas Vogelzang
    Investigational New Drugs, 2009, 27 : 63 - 65
  • [5] A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors
    Chiorean, E. Gabriela
    Malireddy, Srikar
    Younger, Anne E.
    Jones, David R.
    Waddell, Mary-Jane
    Sloop, Melissa I.
    Yu, Menggang
    Hall, Stephen D.
    Schneider, Bryan
    Sweeney, Christopher J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 441 - 448
  • [6] A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors
    E. Gabriela Chiorean
    Srikar Malireddy
    Anne E. Younger
    David R. Jones
    Mary-Jane Waddell
    Melissa I. Sloop
    Menggang Yu
    Stephen D. Hall
    Bryan Schneider
    Christopher J. Sweeney
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 441 - 448
  • [7] Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients
    Speca, J. C.
    Mears, A. L.
    Creel, P. A.
    Yenser, S. E.
    Bendell, J. C.
    Morse, M. A.
    Hurwitz, H. I.
    Armstrong, A. J.
    George, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Phase I and pharmacokinetic (PK) study of PTK787/ZK222584 (PTK/ZK) plus capecitabine (cape) in patients (Pts) with advanced cancer
    Schilsky, R. L.
    Geary, D.
    Skoog, L.
    Desai, A.
    Valickas, J.
    Masson, E.
    Laurent, D.
    Pendowski, C.
    Vokes, E.
    Ratain, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis
    Malireddy, S. R.
    Chiorean, E. G.
    Younger, A.
    Jones, D.
    Waddell, M.
    Margol, M.
    Hall, S.
    Schneider, B. P.
    Sweeney, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis
    Malireddy, S. R.
    Chiorean, E.
    Foster, A.
    Jones, D.
    Waddell, M.
    Margol, M.
    Hall, S.
    Schneider, B.
    Sweeney, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345